NEW YORK (GenomeWeb News) – NuGen Technologies said today that Asuragen’s Pharmacogenomic Services Division will use NuGen’s RNA amplification and labeling products in its gene expression profiling services.
 
The company said Asuragen will use NuGen’s products for its services, which are performed on formalin-fixed paraffin-embedded tissue and whole blood samples on the Affymetrix GeneChip platform.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.

People around the globe took to the streets to support science — some with signs.

Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.

In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.